The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.
 
Eugene Shenderov
Stock and Other Ownership Interests - LifeImmune
Research Funding - Macrogenics (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending in field of allergy immunology and blood diagnostics
 
Angelo Demarzo
Research Funding - Janssen Research & Development; Myriad Genetics
 
Karim Boudadi
No Relationships to Disclose
 
Mohamad Allaf
Research Funding - Progenics (Inst)
 
Hao Wang
No Relationships to Disclose
 
Carolyn Chapman
No Relationships to Disclose
 
Christian Pavlovich
No Relationships to Disclose
 
Trinity Bivalacqua
Honoraria - Photocure
 
Tanya Skelton O'Neal
No Relationships to Disclose
 
Rana Harb
No Relationships to Disclose
 
Rehab Abdallah
No Relationships to Disclose
 
Charles G. Drake
Stock and Other Ownership Interests - Compugen; ImmunExcite; NexImmune; Potenza Therapeutics; Tizona Therapeutics, Inc.
Consulting or Advisory Role - Agenus; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Compugen; Dendreon; ImmuneXcite; Janssen Oncology; Lilly; Merck; NexImmune; Pfizer; Pierre Fabre; Potenza Therapeutics; Roche/Genentech; Tizona Therapeutics, Inc.
Research Funding - Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patents licensed to BMS (Inst); Patents licensed to Potenza Therapeutics (Inst)
 
Drew M. Pardoll
Stock and Other Ownership Interests - Aduro Biotech; Compugen; Jounce Therapeutics; Neximmune; Potenza Therapeutics
Consulting or Advisory Role - Amgen; Medimmune; Merck; Pfizer; Sanofi
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Compugen; Potenza Therapeutics
Patents, Royalties, Other Intellectual Property - Royalties on patents licensed to Aduro, BMS, Potenza
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi